P46410 11th Annual Biosimilars Asia
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

11th Annual Biosimilars Asia

18 – 20 May 2020, Shanghai, China

Book Now

LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

China steadfastly continues to work regulations on biosimilars to help make the market easier to breakthrough, and the recent Priority Review legislation is a case in point. As the industry continues to evaluate cost, risk and incentives for Biosimilar development, new developments to promote R&D and adjustments to approval pathways are designed to help manufacturing and commercialization of biosimilars.

IBC’s 10th Biosimilars Asia is one of 5 conferences part of the 5th Biopharma Development and Production Week in China. It will address the business case, approvals, future manufacturing strategies  and commercialisation, in a market that is expected to be worth $20 billion globally by 2022.

Key Highlights

  • CFDAs priority review policy and impact on biosimilars
  • The current clinical trial landscape for new biosimilars, and expected pipelines
  • The oncology Biosimilars market
  • Future manufacturing strategies
  • Proving similarity
  • Managing product variations
  • Innovation and technology breakthroughs for biosimilar development
  • Pricing and Promotion strategies
  • Commercialisation strategies for the China biosimilars market
  • Anticipating investment across the value chain for successful biosimilar commercialisation

For more information, visit www.biopharmaproduction.com >>

agenda

8:00 am

Main Conference Registration and Morning Coffee

9:00 am

Chairperson’s Opening Remarks

Judith Li, Partner, Lilly Asia Ventures, Hong Kong

5TH BIOPHARMA DEVELOPMENT AND PRODUCTION WEEK 2019 JOINT OPENING PLENARY SESSIONS (8TH CELL LINE DEVELOPMENT, 9TH BIOMANUFACTURING, 10TH BIOSIMILARS, 4TH CLINICAL TRIALS, CELL & GENE THERAPY)

Investor Talk by Lilly Asia Ventures: China’s Great Leap Forward in Biotech

Judith Li, Partner, Lilly Asia Ventures, Hong Kong

9:30 am

  • Recent regulatory developments – obstacle or opportunity?
  • The clinical trials market
  • China market scenarios on CAR-T & CRISPR technology
  • Growth prospects on cell line development market and therapeutics
  • Current state of affairs on biosimilars
  • Digitalization of biopharma value chain – is China ahead of the game?
  • How are new business models creating opportunities?

10:30 am

Morning Networking and Refreshment Break

10TH BIOSIMILARS ASIA COMMENCES

11:20 am

Chairperson’s Opening Remarks

  • Monoclonal antibodies (mAbs) and the oncology market
  • Progression in monoclonal antibodies biosimilars
  • Demand and trends for oncology biologics
  • Innovative programs and partnership highlights for biologics development and CMC capabilities
  • Pipelines, clinical trials and investment updates

12:00 pm

  • Comparison of regulatory requirements
  • How and where to start
  • Choice of reference product
  • Bridging strategies
  • Selected case studies

12:30 pm

Networking Lunch

1:30 pm

  • Scaling up and improving manufacturing quality
  • CDMO’s perspectives on innovative manufacturing
  • What opportunities and challenges exist in developing quality biosimilars in China?
  • Enhance biosimilar adoption by addressing sufficient manufacturing and clinical data to physicians’ acceptance
  • The trends in transformation to world-class GMP facilities

2:10 pm

Fireside Chat: Bioanalytical Challenges and Opportunities for Biosimilars

Dr Zou Linglong, Executive Director, Head of Bioanalytics, Shanghai Henlius Biotech, China

2:50 pm

Future Manufacturing and Technological Strategies for Biosimilars

Frank Ye, Senior Vice President, Technical Operations, Hangzhou JUST Biotherapeutics, China

3:30 pm

Afternoon Networking & Refreshment Break

4:00 pm

  • What are new technology trend for biosimilars manufacturing?
  • Managing new technology and meeting GMP guidelines
  • Biosimilars products development and manufacturing – A spotlight on Enbrel Similar, Filgrastim Similar, Actemra Similar
  • Evaluating manufacturing technology for continuous process development and application to mAb production
  • Tech transfer management

4:30 pm

Combined Q&A Session: Biosimilars Manufacturing Considerations

Dr Dennis Lin, Supervisor, Upstream Process Development, Mycenax Biotech Inc, Taiwan

Dr Lin Shiwen, Vice President of Downstream Process Development, WuXi Biologics, China

5:00 pm

Chairperson’s Summary and End of Main Conference Day One

9:00 am

Chairperson’s Opening Remarks

Asif Mahmood, Disease Area Cluster Lead, Pfizer, USA

9:10 am

  • Innovatives and biosimilars CMC development (fast track to clinical stage)
  • Pathway for parallel submission
  • Challenges in CMC
  • Case Study for FDA/NMPA CTA
  • Global clinical strategy

9:40 am

  • Regulatory requirements for biosimilars safety
  • Clinical studies considerations
  • Formulation, interchangeability and safety considerations

10:30 am

Morning Networking and Refreshment Break

11:50 am

Combined Q&A session: Japan and Chinese Biosimilars

Dr Peter Pang, General Manager, XiKang (Wuhan) Biopharmaceutical Co.Ltd., EVP, Corporate Head of Regulatory Affairs, JHL Biotech Inc, China

Sumimasa Nagai, Deputy Director of the Translational Research Centre / Clinical Expert Advisor at the Office of New Drug V (Oncology) and Companion Diagnostics Working Group, University of Tokyo Hospital / Pharmaceuticals and Medical Devices Agency, Japan

12:20 pm

Networking Lunch

1:40 pm

  • Ensuring identical amino acid sequences
  • Managing biochemical, biophysical, and biological similarities for bioequivalence
  • Case studies – tech, R&D, data and similarity analysis

3:10 pm

Combined Q&A for China and USA Biosimilars Markets

Dr Wu Youling, Chief Executive Officer, ZheJiang Teruisi Biopharmaceutical, China

Dr Jiang Weidong, Vice President and Chief Scientific Officer, Shanghai Henlius Biotech, China

Asif Mahmood, Disease Area Cluster Lead, Pfizer, USA

Wang Yongzhong, President of Pharmaceuticals, Executive Vice President, Simcere Pharmaceutical Group, China

3:30 pm

Afternoon Networking & Refreshment Break

BDP CHINA CLOSING PLENARY SESSION

5:00 pm

Chairperson’s Summary and End of Main Conference Day Two

9:00 am

China’s biopharma industry continues to grow rapidly  and hails as a major investment region in the world. With tides of tech innovation, market growth in CRO, CMO and CDMO, a numerous clinical trials projects lined-up, newly discovered therapies to the market and upgrading manufacturing facilities to name a few. This workshop aims to provide a strategic snapshot of the investment landscape for biopharma medicine, and covers practical aspects on how biotech companies can navigate the investment and pricing options for related drugs and treatments to generate better returns.

You will learn:

  • Financing clinical trials operations
  • R&D investment and financing models
  • Manufacturing financing
  • Financial partnership with Chinese pharma and biotech
  • Biosimilars products financing
  • Going Public and Listing insights
  • Deal, debt and equity structuring

1:00 pm

End of Workshop

pricing

Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895US $1695Early BirdEarly Bird
Group Rate of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group Rate of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
2 Day Conference - Local China CompaniesUS $977US $827Early BirdEarly Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird
Extras Price
Pre Conference Workshop - International Companies, Global HQ Located Outside China US $300
Pre Conference Workshop - Local China Companies US $150
Gala Dinner US $50

Early Bird Rate: Register & Pay by 27 March 2020

Group Rate – Local China Companies

  • Group of 2 or more delegates  = US $752
  • Group of 4 or more delegates  = US $676

Group Rate – International Companies, Global HQ Located Outside China

  • Group Rate of 2 or more delegates   = US $1495
  • Group Rate of 4 or more delegates  = US $1295

For Group Registrations : email info@ibcasia.com.sg or call +65 6508 2477

 

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)
  • View payment terms and bank transfer details, click here »

CNY Pricing

  • 2 Day Conference: CNY 6,500
  • Group of 2 or more delegates: CNY 5,000
  • Group of 4 or more delegates: CNY 4,500
  • Pre Conference Workshop: CNY 1,000
  • Gala Dinner: CNY 350

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

Exhibition Floorplan >>

speakers

Judith Li

Partner, Lilly Asia Ventures, Hong Kong

Feng Tao

Founding Partner, Biotrack Capital, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Peter Luo

CEO, Adagene Pharma, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

Co-Founder and Executive Chairman, TRANSCENTA HOLDING, China

Dr Wu Youling

Chief Executive Officer, ZheJiang Teruisi Biopharmaceutical, China

Dr. Manfred Weiler

Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Dr Zou Linglong

Executive Director, Head of Bioanalytics, Shanghai Henlius Biotech, China

Frank Ye

Senior Vice President, Technical Operations, Hangzhou JUST Biotherapeutics, China

Dr Dennis Lin

Supervisor, Upstream Process Development, Mycenax Biotech Inc, Taiwan

Asif Mahmood

Disease Area Cluster Lead, Pfizer, USA

Dr Peter Pang

General Manager, XiKang (Wuhan) Biopharmaceutical Co.Ltd., EVP, Corporate Head of Regulatory Affairs, JHL Biotech Inc, China

Sumimasa Nagai

Deputy Director of the Translational Research Centre / Clinical Expert Advisor at the Office of New Drug V (Oncology) and Companion Diagnostics Working Group, University of Tokyo Hospital / Pharmaceuticals and Medical Devices Agency, Japan

Dr Jiang Weidong

Vice President and Chief Scientific Officer, Shanghai Henlius Biotech, China

Wang Yongzhong

President of Pharmaceuticals, Executive Vice President, Simcere Pharmaceutical Group, China

Dr Jerry Dong

Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr. Jerry Yang

Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics, China

Xiaodi Su

Senior Investment Manager, Lilly Asia Ventures, China

Jieyu Zou

Vice President, Lilly Asia Ventures, China

when & where

18 - 20 May 2020

contact

Still have a question?

sponsors

exhibitors

Partners

Conference Partner Conference Partner

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more

We are changing our brand to Informa Connect
Learn More
close-image